Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
Recruitment unclearEUCTR 2005-003156-35
Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and Addiction: A randomised study
This historical record does not confirm current site availability.
Historical research recordGermany
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Germany
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 50
- Sponsor
- Department of Psychiatry and Psychotherapy (Cologne)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-003156-35
- Official title
Show the full official title
Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study
Recruitment & locations
Status unknownGermany
Registry details
Historical country statuses
- Germany — Ongoing
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Department of Psychiatry and Psychotherapy (Cologne).
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Recruitment unclearEUCTR 2013-001694-24
A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...
France, United Kingdom, Belgium, + 6 others
Recruitment unclearEUCTR 2016-003435-38
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Bulgaria, Croatia, Czechia, + 6 others
Recruitment unclearEUCTR 2022-001515-10
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease Deme...
France, Bulgaria, Germany, + 3 others